CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease
Company Expects Phase 2 Data with Second Drug Candidate (CST-103) in Neurodegenerative Diseases in Third Quarter of 2022
Excerpt from the Press Release:
SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032, a novel, oral beta-2 adrenoceptor (β2-AR) agonist. The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease. CST-2032 is administered in combination with CST-107, a β-AR blocker, to minimize known side effects of β2-AR agonists. The multi-center trial, which is expected to enroll approximately 40 patients, is being conducted in the United States and New Zealand.
“With this trial initiation, CuraSen now has two unique pipeline opportunities in ongoing Phase 2 clinical studies aimed at improving the debilitating cognitive symptoms and loss of function in neurodegenerative diseases, with the ultimate goal of preventing or even reversing disease progression,” said Anthony Ford, PhD, chief executive officer, CuraSen Therapeutics.
The company’s two distinct drug candidates, CST-2032 and CST-103, target brain β2-ARs to directly activate cell types normally regulated by healthy adrenergic function. The stimulatory activation of these cells, which include neurons, microglia, pericytes and astrocytes, helps compensate for critical brain functions lost early in the disease process due to adrenergic decline. In addition, this mechanism of action helps maintain cognition and restore complex pathways vital for protecting brain health. The β-AR antagonist, CST-107, is co-administered to help manage common peripheral side effects of β2-AR agonists, such as increased heart rate, that might otherwise limit dosing below optimal cerebral impact.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?